Kyowa Kirin Co., Ltd. (KYKOF)
OTCMKTS · Delayed Price · Currency is USD
17.13
+2.38 (16.14%)
At close: Jul 28, 2025
Kyowa Kirin Employees
Kyowa Kirin had 5,669 employees as of December 31, 2024. The number of employees decreased by 305 or -5.11% compared to the previous year.
Employees
5,669
Change (1Y)
-305
Growth (1Y)
-5.11%
Revenue / Employee
$603,054
Profits / Employee
$46,965
Market Cap
8.67B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5,669 | -305 | -5.11% |
Dec 31, 2023 | 5,974 | 222 | 3.86% |
Dec 31, 2021 | 5,752 | 329 | 6.07% |
Dec 31, 2020 | 5,423 | 156 | 2.96% |
Dec 31, 2019 | 5,267 | -1,975 | -27.27% |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Elite Pharmaceuticals | 68 |
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
Northwest Biotherapeutics | 25 |
CytoDyn | 13 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Kyowa Kirin News
- 5 days ago - Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis - Benzinga
- 5 days ago - Amgen (AMGN) and Kyowa Kirin Report Positive Long-term Results for Rocatinlimab - GuruFocus
- 5 days ago - Amgen, Kyowa Kirin announce long-term Phase 3 data for eczema drug - Seeking Alpha
- 5 days ago - Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from ASCEND Study on Rocatinlimab ... - GuruFocus
- 5 days ago - Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Results from Rocatinlimab Phase 3 ASCEND ... - GuruFocus
- 26 days ago - Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers - GlobeNewsWire
- 6 weeks ago - Kyowa Kirin Co., Ltd. (KYKOF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress - PRNewsWire